Company news
Vortex Energy Corp. (CSE:VRTX) news
Every Vortex Energy Corp. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Vortex Energy Engages Lonquist to Manage Ground Gravity Survey at the Robinsons River Salt Project
September 14, 2026
Vortex Energy Announces Plans for Ground Gravity Survey at the Robinsons River Salt Project
September 3, 2026
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
September 1, 2026
Vortex Energy Announces Final Ambient Noise Tomography Results for the Robinsons River Salt Project
August 18, 2026
Vertex Reports Second Quarter 2026 Financial Results
August 3, 2026
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
July 29, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq - TCBK), Twin Vee Power...
July 21, 2026
Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study
July 16, 2026
Vortex Energy Corp. Announces Closing of LIFE Offering
July 13, 2026
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
July 8, 2026
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
July 7, 2026
Vertex to Acquire Crinetics Pharmaceuticals
July 6, 2026
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Di...
July 1, 2026
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5-11, at the European Hematolog...
June 11, 2026
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
June 5, 2026
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
June 3, 2026
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
June 1, 2026
Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Sever...
May 21, 2026
Vertex to Participate in Upcoming May Investor Conferences
May 11, 2026
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemi...
May 6, 2026
Vertex Reports First Quarter 2026 Financial Results
May 4, 2026
Vortex Energy Announces Intent to Advance Next Phase of Technical Work at the Robinsons River Salt Project and Engages Lonquist
April 30, 2026
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Ge...
April 10, 2026
Vertex to Announce First Quarter 2026 Financial Results on May 4th
April 6, 2026
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ...
April 1, 2026
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
March 24, 2026
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Poveta...
March 9, 2026
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
March 5, 2026
Vortex Energy Announces Postponement of AGM
February 18, 2026
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
February 17, 2026
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
January 26, 2026
Vortex Energy Highlights 2025 Technical Milestones Across Project Portfolio and Announces Adjournment of AGM to February 13, 2026
January 21, 2026
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
January 20, 2026
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 11, 2026
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
January 2, 2026
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
December 22, 2025
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
December 16, 2025
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology A...
December 6, 2025
Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3
November 19, 2025
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults ...
November 8, 2025
Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention
November 4, 2025
Vertex Reports Third Quarter 2025 Financial Results
November 3, 2025
Vertex to Participate in the UBS Global Healthcare Conference on November 11
October 27, 2025
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Con...
October 23, 2025
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
October 17, 2025
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
October 6, 2025
Vertex Announces Key Advancements Across Kidney Portfolio
September 25, 2025
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the ...
September 23, 2025
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Diseas...
September 18, 2025